The effect of combination therapy with Metformin and combined Cyproterone Acetate/Ethinyloestradiol on PCOS patients

LIU Jin-xia,DANG Jie-ming,WU Yuan-zhe,ZHENG Ning,WU Xiao-ke
DOI: https://doi.org/10.3969/j.issn.1008-8199.2006.06.014
2006-01-01
Abstract:Objective:Insulin resistance and hyperandrogenism are the characteristics of patients with polycystic ovary syndrome(PCOS).The paper evaluated the therapeutic effects of metformin and Cyproterone Acetate/Ethinyloestradiol(Diane35) in PCOS patients. Methods:This clinical study lasted 6 months and included 60 women with PCOS,which divided into three groups of 20 women each.metformin Group received metformin alone,combined therapy group Ⅰ treated with metformin and Diane35,combined therapy group Group Ⅱ in which Diane35 was added to the same treatment only during the first 3 months of the investigation.Serum levels of Luteinizing hormone(LH),testosterone(T),fasting insulin(FINS),sex hormone binding globulin(SHBG),dehydroepiandrosterone sulfate(DHEAS),fasting glucose and lipid metabolism parameters were measured before the treat,on the third and sixth month.Free androgen index and insulin sensitivity index were calculated.Body mass index and waist to hip ratio were assessed before and after the therapy. Results:Patients in the metformin group had significant decrease in T,FINS and AFI,and a significant increase in SHBG.Compared to metformin group,groups with combined use of metformin and Diane35 had more significant changes in these parameters.There were no difference between 6 months and 3 months of Diane35 treatment.Conclusion:The PCOS patients treated with metformin and Diane35 might be more effective compared with metformin alone.The combination of metformin with intermittent application of Diane35 is an appropriate alternative for PCOS patients intented for conception.
What problem does this paper attempt to address?